Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16459758 | 0.86 | LMNA (0.47) | LMNAHRH3CYP2D6MMP9KDM4E | |
| SCHEMBL16460055 | 0.84 | LMNA (0.46) | LMNAHRH3CYP2D6KDM4EMAPT | |
| SCHEMBL16460189 | 0.84 | LMNA (0.50) | LMNAHRH3CYP2D6KDM4EMAPT | |
| SCHEMBL16459165 | 0.84 | LMNA (0.62) | LMNAHRH3CYP2D6MMP9KDM4E | |
| SCHEMBL16459040 | 0.84 | LMNA (0.46) | LMNATAAR1HRH3CYP2D6MMP9 | |
| SCHEMBL12471989 | 0.84 | LMNA (0.66) | LMNAHRH3CYP2D6KDM4EMAPT | |
| SCHEMBL16459020 | 0.82 | MEN1 (0.45) | LMNAHRH3KDM4EMAPTNPC1 | |
| SCHEMBL1763999 | 0.78 | KDM4E (0.51) | LMNATAAR1HRH3CYP2D6KDM4E | |
| SCHEMBL16475556 | 0.77 | LMNA (0.42) | LMNAHRH3CYP2D6KDM4EMAPT | |
| SCHEMBL16459946 | 0.77 | LMNA (0.46) | LMNAKDM4EMAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969585-B2 | Method for producing optically active compound or salt thereof | NAGASAKI UNIVERSITY (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969585-B2 | Method for producing optically active compound or salt thereof | NAGASAKI UNIVERSITY (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969585-B2 | Method for producing optically active compound or salt thereof | NAGASAKI UNIVERSITY (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140012010-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF | NAGASAKI UNIVERSITY (JP) | 2014-01-09 | — | — | US | disclosed |
| US-20140012010-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF | NAGASAKI UNIVERSITY (JP) | 2014-01-09 | — | — | US | disclosed |
| US-20140012010-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF | NAGASAKI UNIVERSITY (JP) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140012010-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF | MINK1, MELK, MRPL21 | LMNA 1949/4885TAAR1 1939/4885HRH3 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.